Breaking News

Novozymes Begins Commercial Supply From China Facility

Initiates first shipment of Hyasis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novozymes Biopharma has initiated the first shipment of its Bacillus-derived hyaluronic acid, Hyasis, from its new manufacturing facility in China. The first commercial products using Hyasis as a raw material are expected to reach the market in 2Q12.   “Shipment of the first commercial hyaluronic acid material from our new Q7 GMP facility marks an important milestone on our journey to becoming a leading producer of high quality hyaluronic acid. With our new patented process, based on the safe ba...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters